Jump to content

Fundación Jiménez Díaz
  • Quirónsalud
  • Doubts and queries
  • Site map
  • Twitter This link will open in a pop-up window.
  • Facebook This link will open in a pop-up window.
  • Youtube This link will open in a pop-up window.
  • Linkedin This link will open in a pop-up window.
  • Instagram This link will open in a pop-up window.
  • TikTok Link to external application.
  • Private appointment
  • Patient Portal Link to external application.
Language selector
Active language English
  • español
  • English
  • International version
    • Español Link to external application.
    • English Link to external application.
    • Deutsch Link to external application.
    • Pусский Link to external application.
    • العربية Link to external application.
    • Français Link to external application.
Location and transport
91 550 48 00 / 900 606 055 / Private Care: 91 090 05 16
  • Medical directory
  • Insurance companies and mutuals
  • Services portfolio
  • Our centre
    • Why choose our centre?
    • Location and transport
    • Contact information
    • Opening hours
    • Map of the centre
    • Facilities and services
    • History
    • Management structure
    • Mission, vision and values
    • Quirónsalud Group This link will open in a pop-up window.
    • Reports
    • Quality
    • Recognitions and certifications
    • Fundación Conchita Rábago
    • Programa de Alimentación Saludable
  • Actividades
  • Media section
    • News
    • Videos
    • Podcast
    • Contenidos de salud
    • Calendar of events
    • Photo and multimedia gallery
    • Virtual visits
    • 75th Anniversary FJD
  • Work with us This link will open in a pop-up window.
  • Patients and visitors
  • Research
  • Teaching
Teléfono de atención al usuario900 301 013
  • Home
  •   |   Services portfolio
  •   |   Haematology and Haemotherapy
  •   |   Ensayos clínicos
  •   |   Linfomas no Hodgkin

Haematology and Haemotherapy

Situation: Entrance Plaza Cristo Rey. Outpatient Consultations, Floor 1, Lifts 2 and 3. Hospitalisation, Unit 36, Floor 6, Lift 1 Blood Bank and Blood Donation, Ground Floor (after the Blood Draw Room).
Phone: 915504800
E-mail: hematologia.fjd@fjd.es
Head of department: Dra. Maria Pilar Llamas Sillero
Opening times: Monday 10 a.m. to 8:30 p.m. Tuesday. Wednesday. Thursday. Friday: 10 a.m. to 8.30 p.m. until further notice: Public holidays. No blood donation at weekends or at Quintana Specialist Centre.
Description
  • Equipo Médico
  • Facilities, Techniques and Procedures
  • Information for Patients
  • Subspecialities and Units
  • Research and teaching
  • Recognitions and Accreditations
Linfomas no Hodgkin
  • Ensayo fase III aleatorizado, doble ciego, controlado con placebo para comparar la eficacia, seguridad y farmacocinética de GP2013 más Ciclofosfamida, Vincristina, Prednisona frente a Mabthera más Ciclofosfamida, Vincristina, Prednisona, seguido de tratamiento de mantenimiento con GP2013 o Mabthera en pacientes con Linfoma Folicular en estado avanzado no tratado previamente
  • Ensayo clínico Fase IIIb abierto, no controlado, para evaluar la seguridad del cambio de Rituximab intravenoso a Rituximab subcutáneo durante el tratamiento de primera línea de Linfoma no Hodgkin Folicular y Difuso de Células B grandes CD20 positivos
  • Estudio de Fase 3, doble ciego y aleatorizado para comparar la eficacia y seguridad de Rituximab más lenalidomida (CC-5013) frente a Rituximab más placebo en sujetos con Linfoma indolente recidivante o en recaída
  • Estudio Fase 3, aleatorizado, doble ciego y controlado con placebo, del inhibidor de la tirosina quinasa de bruton PCI-32765 (Ibrutinib) en combinación con Bendamustina-Rituximab o con R-CHOP en sujetos con linfoma no Hodgkin indolente previamente tratado
  • A phase 1 study of the safety, tolerability, pharmacokinetics and immunoregulatory activity of Urelumab (BMS-663513) in subjects with advanced and or metastatic solid tumors and relapsed/refractory B-cell non-Hodgkin's Lymphoma
  • A Phase 1a/1b, Multi-Center, Open-Label, Dose Finding Study to Assess the Safety,Tolerability, Pharmacokinetics and Preliminary Efficacy of the Pleiotropic Pathway Modifier CC-122 Administered Orally to Subjects with Advanced Solid Tumors, Non-Hodgkin’s Lymphoma or Multiple Myeloma
  • A randomized, double-blind, parallel-arm, Phase I study to evaluate the pharmacokinetics and pharmacodynamics of BI 695500 vs. Rituximab (MabThera) induction immunotherapy as a first-line treatment in patients with low tumor burden follicular lymphoma
  • A phase 2, open label, multicenter, multiarm study of ceritinib in patients with advanced solid tumors and hematological malignancies characterized by genetic abnormalities of anaplastic lymphoma kinase (ALK)
  • Estudio de Fase 3, doble ciego, aleatorizado, controlado con placebo, y multicéntrico para comparar la eficacia y seguridad de Lenalidomida (CC-5013) más quimioterapia con R-CHOP (R2-CHOP) frente a placebo más quimioterapia con R-CHOP en sujetos con linfoma difuso de células B grandes activadas que no han recibido tratamiento con anterioridad
Services portfolio
  • Nuestros blogs
  • Tu canal de salud - Noticias y consejos de salud
  • Programa de Seguimiento del Embarazo
  • Portal del paciente
banner quironsalud gris
Location and transport

Hospital Universitario Fundación Jiménez Díaz

Avda. Reyes Católicos, 2
28040 Madrid Madrid

91 550 48 00 / 900 606 055 / Private Care: 91 090 05 16
  • Contact
  • Map of web
  • Disclaimer
  • Data protection
  • Cookies policy
  • Accessibility
Joint Commission International
  • Twitter This link will open in a pop-up window.
  • Facebook This link will open in a pop-up window.
  • Youtube This link will open in a pop-up window.
  • Linkedin This link will open in a pop-up window.
  • Instagram This link will open in a pop-up window.
  • TikTok Link to external application.

© 2025 Quirónsalud - All rights reserved